Krystal Biotech, Inc. $KRYS Stock Holdings Boosted by Vontobel Holding Ltd.

Vontobel Holding Ltd. grew its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 13.9% in the second quarter, according to its most recent filing with the SEC. The fund owned 3,075 shares of the company’s stock after acquiring an additional 375 shares during the period. Vontobel Holding Ltd.’s holdings in Krystal Biotech were worth $423,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Maryland State Retirement & Pension System lifted its position in shares of Krystal Biotech by 1.7% during the 2nd quarter. Maryland State Retirement & Pension System now owns 7,474 shares of the company’s stock valued at $1,027,000 after acquiring an additional 123 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Krystal Biotech by 15.8% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,116 shares of the company’s stock valued at $153,000 after acquiring an additional 152 shares during the last quarter. Tealwood Asset Management Inc. acquired a new stake in shares of Krystal Biotech during the 2nd quarter valued at $1,125,000. Tempus Wealth Planning LLC acquired a new stake in shares of Krystal Biotech during the 2nd quarter valued at $327,000. Finally, State of Alaska Department of Revenue lifted its holdings in shares of Krystal Biotech by 7.9% in the second quarter. State of Alaska Department of Revenue now owns 15,130 shares of the company’s stock valued at $2,079,000 after purchasing an additional 1,106 shares in the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on the company. HC Wainwright restated a “buy” rating and issued a $240.00 target price on shares of Krystal Biotech in a report on Monday, September 15th. Weiss Ratings restated a “hold (c)” rating on shares of Krystal Biotech in a report on Wednesday, October 8th. Chardan Capital reduced their target price on Krystal Biotech from $219.00 to $216.00 and set a “buy” rating for the company in a report on Friday, August 22nd. Bank of America reduced their target price on Krystal Biotech from $193.00 to $192.00 and set a “buy” rating for the company in a report on Tuesday, July 22nd. Finally, Citigroup reiterated a “neutral” rating and set a $166.00 price objective (down from $176.00) on shares of Krystal Biotech in a report on Tuesday, August 5th. Six investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, Krystal Biotech currently has an average rating of “Moderate Buy” and a consensus target price of $209.00.

Krystal Biotech Price Performance

Krystal Biotech stock opened at $188.05 on Wednesday. The company has a market capitalization of $5.44 billion, a price-to-earnings ratio of 38.22 and a beta of 0.64. Krystal Biotech, Inc. has a one year low of $122.80 and a one year high of $207.84. The company’s fifty day moving average price is $157.48 and its two-hundred day moving average price is $151.04.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, August 4th. The company reported $1.29 EPS for the quarter, topping the consensus estimate of $1.08 by $0.21. The firm had revenue of $96.04 million for the quarter, compared to the consensus estimate of $95.42 million. Krystal Biotech had a net margin of 40.85% and a return on equity of 15.21%. As a group, sell-side analysts anticipate that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).